A Phase I, Open-Label, Two-Part Study of the Effect of Multiple-Dose Evobrutinib on Transporter Substrates Digoxin, Metformin, Rosuvastatin, and Sumatriptan Pharmacokinetics in Healthy Participants
Latest Information Update: 14 Jan 2022
At a glance
- Drugs Evobrutinib (Primary) ; Digoxin; Metformin; Rosuvastatin; Sumatriptan
- Indications Encephalomyelitis; Multiple sclerosis
- Focus Pharmacokinetics
- Sponsors Merck KGaA
- 10 Jan 2022 Status changed from recruiting to completed.
- 10 Nov 2021 Status changed from not yet recruiting to recruiting.
- 07 Oct 2021 New trial record